Ameriprise
KPTI icon

Ameriprise’s Karyopharm Therapeutics KPTI Stock Holding History

Ameriprise’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-276,881
Closed -$2.04M – 4153
2025
Q4 		$2.04M Buy
+276,881
New +$1.69M ﹤0.01% 2992
2024
Q1 		– Sell
-20,664
Closed -$268K – 3919
2023
Q4 		$268K Sell
20,664
-3,135
-13% -$42.2K ﹤0.01% 3641
2023
Q3 		$478K Sell
23,799
-211
-0.9% -$4.74K ﹤0.01% 3431
2023
Q2 		$645K Buy
24,010
+6,820
+40% +$294K ﹤0.01% 3344
2023
Q1 		$1M Buy
17,190
+6,191
+56% +$306K ﹤0.01% 3152
2022
Q4 		$560K Sell
10,999
-336
-3% -$23.3K ﹤0.01% 3357
2022
Q3 		$929K Buy
+11,335
New +$847K ﹤0.01% 3146
2017
Q2 		– Sell
-5,859
Closed -$1.13M – 3769
2017
Q1 		$1.13M Buy
+5,859
New +$940K ﹤0.01% 2836
2014
Q4 		– Sell
-1
Closed -$1K – 4081
2014
Q3 		$1K Buy
+1
New +$564 ﹤0.01% 5554
2014
Q2 		– Sell
-1,825
Closed -$845K – 5617
2014
Q1 		$845K Buy
+1,825
New +$925K ﹤0.01% 2789

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Ameriprise's KPTI Position: Q1 2026 in Review

Ameriprise sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 276,881 shares — an estimated $2.04M sold.

Ameriprise first reported a position in KPTI in Q1 2014 and held it in 10 quarters. The position peaked at $2.04M in Q4 2025. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Ameriprise reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 276,881 Karyopharm Therapeutics shares in Q1 2026, an estimated $2.04M.
  • Ameriprise first reported a position in Karyopharm Therapeutics in Q1 2014 and held it in 10 quarters.
  • Ameriprise's Karyopharm Therapeutics position peaked at $2.04M in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.